----
Current ValuationThe current P/E ratio is 29.61, above the reasonable range, cheaper than 13.88% of the time in the past 5 years, and the industry ranks 45/255, the industry Median -1.27.
29.61xP/E
$258.45Stock price
$8.73Earnings per share
29.61xP/E
Stock price$258.45Earnings per share$8.73
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 23.12x
- Typical range
- 11.80x–26.69x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0285684112
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
JNJUSJohnson & Johnson | 29.61x | 18.50% | $622.84B |
RHHBYUSRoche | 22.29x | -- | $344.65B |
RHHVFUSROCHE HOLDINGS AG | 23.74x | -- | $367.09B |
NVSUSNOVARTIS AG | 21.35x | 0.96% | $272.33B |
AZNUSAstraZeneca | 23.77x | -- | $248.34B |
SNYNFUSSanofi | 20.73x | -- | $95.23B |
SNYUSSanofi | 20.96x | 23.01% | $96.32B |
MKKGYUSMerck | 24.79x | -- | $68.19B |
CHGCYUSChugai Pharmaceutical | 21.10x | -- | $63.54B |
RDYUSDr Reddys Laboratories | 28.37x | 11.62% | $10.22B |
LGNDUSLigand Pharmac-B | 29.64x | 14.77% | $5.85B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
